Back

Direct comparison of dabigatran, apixaban, rivaroxaban and edoxaban for effectiveness and safety among patients with non-valvular atrial fibrillation

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 5 - Atrial fibrillation and oral anticoagulation 5 Oral Anticoagulation ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Eue-Keun Choi

Seoul National University Hospital, Seoul (Korea (Republic of))

8 More presentations in this session

Presentation thumbnail
Treatment persistence of patients with atrial fibrillation on VKA or NOAC: Data from GLORIA-AF Phase III 1-year interim analysis
Professor G. Lip (Liverpool, GB)
Abstract Slides
Presentation thumbnail
Efficacy and safety of dronedarone by duration of atrial fibrillation history: a post-hoc analysis of the ATHENA trial
Professor M. Blomstrom-Lundqvist (Orebro, SE)
Abstract Slides
Presentation thumbnail
Clinical characteristics and 1-year outcomes in atrial fibrillation patients with or without history of intracranial haemorrhage treated with edoxaban: snapshot analysis of the Global ETNA-AF program
Professor P. Kirchhof (Hamburg, DE)
Abstract
Presentation thumbnail
Dual antithrombotic therapy is similarly effective to triple therapy in preventing thrombotic events in patients with atrial fibrillation and acute coronary syndrome
Professor Z. Motovska (Prague, CZ)
Abstract Slides
Presentation thumbnail
Use of direct oral anticoagulants in patients with atrial fibrillation having a history of intracranial hemorrhage
Doctor T. Chao (Taipei, TW)
Abstract

Access the full session

Session thumbnail
Poster Session 5 - Atrial fibrillation and oral anticoagulation 5

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Session
Stroke prevention in clinical and subclinical atrial fibrillation
thumbnail
Congress Presentation
Interactive discussion and Q&A
thumbnail
Congress Presentation
State-of-the-art lecture on stroke and bleeding risk in atrial fibrillation: walking the tight rope

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources